An interventional study of DBT-informed milieu therapy and Treatment as usual in Substance Abuse Disorder, Dialectical Behavior Therapy and Emotion Management Skills, sponsored by Helse Møre og Romsdal HF. Enrolling by invitation at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.
Sponsored by Helse Møre og Romsdal HF · Not applicable, Interventional, and Treatment
Among 41 studies in Substance-Related Disorders with a site in Norway — 8 open to participants now, 15 under way, none of them phase 3. Substance-Related Disorders · Norway.
Among the 41 studies in Substance-Related Disorders with a site in Norway, this one is the 20th largest by planned enrollment of the 28 interventional ones that give a count, is one of 2 that started in 2026, is one of 23 with no phase, reaches primary completion later than 10 of the 14 other live ones, and was the 41st registered.
2,238 studies on the registry are indexed under Substance-Related Disorders; 409 are open to participants now.
Browse Substance-Related Disorders studies →8 of the 41 studies in Substance-Related Disorders with a site in Norway are open now. Recruiting first, the newest first:
NORCE Norwegian Research Centre AS · Sites in Norway, Austria, Israel and 5 more countries
Oral Health Center of Expertise Rogaland, Norway · Sites in Norway
Sykehuset Innlandet HF · Sites in Norway
University Hospital of North Norway · Sites in Norway
Norwegian University of Science and Technology · Sites in Norway
A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →
Of the 266 Substance-Related Disorders studies recruiting now, 130 (49%) set no upper age limit and 118 (44%) stop at 75 or younger; 56 take children under 18; 89 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 4 · Phase 4 1
First in 2003; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 82 is below the median of 108 across 1,840 interventional studies indexed under Substance-Related Disorders.
Median enrollment 138 across the 28 interventional studies, 262 across the 13 observational. Of the 24 that completed or were terminated, 1 (4%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 41 has an industry lead sponsor. The 10 most frequent:
Helse Møre og Romsdal HF is the lead sponsor of 24 studies on the registry; 7 are open to participants now.
Helse Møre og Romsdal HF has 1 study filed under Substance-Related Disorders — fewer than ten, so there is no comparison to draw.
2 of the studies in Substance-Related Disorders with a site in Norway that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06933342Oral Health Center of Expertise Rogaland, NorwayASD and Habituation to Dental Examination | 2026-12 |
| NCT07693439Helse Møre og Romsdal HFImplementing DBT in Short-Term SUD-treatment | 2027-03-30 |
Among the 41 studies in Substance-Related Disorders with a site in Norway, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main objective of the study is to provide new knowledge about the implementation of DBT-informed environmental therapy in short-term substance use disorder (SUD) inpatient treatment. The study will examine which organizational and clinical conditions promote or inhibit implementation in clinical practice by elucidating how the implementation is experienced by staff (including experiences with structure, skill focus and environmental therapeutic principles) related to DBT-informed environmental therapy, DBT-SUD skill groups and patients' perceived satisfaction and utility.
A secondary and exploratory aim is to examine preliminary trends in clinical measures in patients over time, including changes in symptom burden and reported use of DBT skills throughout the course of treatment. The study further seeks, at a descriptive and hypothesis-generating level, to explore patterns in patient-reported conditions related to substance abuse, emotion regulation, and other clinical burden. The sample will consist of up to 70 adult patients and 12 staff. One half of the patients will receive ordinary short-term inpatient treatment, while the other half will receive DBT informs milieu therapy after the approach has been established in clinical practice without being implemented. All patients will complete questionnaires upon admission (baseline), week 6 and upon discharge (week 12).
This pilot implementation study evaluates the introduction of DBT-informed milieu therapy in a short-term inpatient substance use disorder (SUD) treatment unit. The study aims to investigate the feasibility, acceptability, and fidelity of implementing DBT-informed milieu therapy in routine clinical practice, as well as to explore preliminary trends in patient-reported clinical outcomes.
The study uses a sequential A-B design. During Phase A, patients receive treatment as usual (TAU), consisting of standard short-term inpatient SUD treatment. During Phase B, DBT-informed milieu therapy is implemented as part of routine care following staff training and integration of DBT-informed principles and skills into daily clinical practice.
Implementation outcomes are assessed at the unit level and include measures of fidelity, feasibility, acceptability, and adherence to planned implementation activities. Data sources include implementation records, staff questionnaires, and qualitative interviews with staff members involved in the implementation process.
Patient-reported clinical outcomes are collected to explore changes during treatment and to generate hypotheses for future studies. Outcomes include emotion regulation, borderline symptom severity, DBT-related coping skills, alcohol use, and drug use. Data are collected at admission (baseline), week 6, and discharge when applicable.
The study is conducted in a multidisciplinary specialized substance use disorder treatment service. Adult patients admitted to the participating short-term inpatient unit are recruited consecutively during the study period. The study is intended to provide knowledge about factors that facilitate or hinder implementation of DBT-informed milieu therapy and to inform future larger-scale evaluations.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adults aged 18 years or older. Admitted to the participating short-term inpatient substance use disorder treatment unit during the study period.
Able and willing to provide written .
Exclusion Criteria
Unable to understand study information. Unable to provide . Severe cognitive impairment or other conditions preventing meaningful participation in study procedures.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients receiving short-term inpatient SUD treatment after implementation of DBT-informed milieu therapy.
Behavioral: DBT-informed milieu therapy
Patients receiving standard short-term inpatient SUD treatment before implementation of DBT-informed milieu therapy.
Behavioral: Treatment as usual
Implementation of DBT-informed milieu therapy, including staff training and integration of DBT-informed principles and skills into daily inpatient treatment.
Standard short-term inpatient SUD treatment including milieu therapy, individual counseling, group-based interventions and pharmacological treatment according to routine clinical practice.
Fidelity to DBT-informed milieu therapy implementation
Degree of implementation of DBT-informed milieu therapy at the unit level, assessed through documentation of staff training, implementation activities and adherence to planned DBT-informed practices, and feedback from staff and patients.Fidelity assessed through implementation records, staff questionnaires and qualitative staff interviews.
Time frame: During the 12 week implementation period.
Emotion regulation (DERS 16 total score)
Total score on the Difficulties in Emotion Regulation Scale-16. Higher scores indicate greater difficulties in emotion regulation.
Time frame: Baseline, 6. weeks and discharge (12 weeks)
DBT coping skills (DBT-WCCL)
Use of coping skills assessed with the DBT Ways of Coping Checklist (DBT-WCCL). The instrument measures the use of DBT-consistent coping strategies during treatment.
Time frame: Baseline, 6 weeks and Discharge (12 weeks)
Borderline symptom List (BSL-23)
Total score on the Borderline Symptom List-23 (BSL-23). Higher scores indicate greater severity of borderline-related symptoms.
Time frame: Baseline, 6 Weeks and Discharge (12 weeks)
Alcohol use (AUDIT total score)
Alcohol use and alcohol-related problems assessed using the Alcohol Use Disorders Identification Test (AUDIT). Higher scores indicate greater alcohol-related risk and problems
Time frame: Baseline and Discharge (12 weeks)
Drug use (DUDIT total score)
Drug use and drug-related problems assessed using the Drug Use Disorders Identification Test (DUDIT). Higher scores indicate greater drug-related risk and problems.
Time frame: Baseline and Discharge (12 weeks)
Plan to share: No — It has not yet been determined whether de-identified individual participant data will be made available. Any future data sharing will be subject to applicable ethical approvals, institutional policies, data protection regulations, and participant consent.
Started Jul 2026 (actual). Primary completion is estimated for Mar 2027, 8 months after the start.
Of 814 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's planned 8 months is below that.
Counting every sponsor, half of 854 studies reached it within 34 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Helse Møre og Romsdal HF